Oral bioavailability and disposition of [14C]omapatrilat in healthy subjects.
The objective of this study was to determine the absolute oral bioavailability and disposition of omapatrilat. This single-dose, randomized, crossover study of 20 mg intravenous and 50 mg oral [14C]omapatrilat was conducted in 12 healthy male subjects to determine the disposition and oral bioavailability of omapatrilat, an orally active vasopeptidase inhibitor. Blood samples were collected up to 120 hours, and the excreta were collected over 168 hours postdose. Plasma concentrations of omapatrilat were determined by a validated LC/MS/MS procedure. Radioactivity in blood, plasma, urine, and feces was determined by liquid scintillation counting. Urinary excretion of radioactivity averaged 80% and 64% of intravenous and oral doses, respectively; < 1% of oral dose was excreted unchanged in urine. The absolute oral bioavailability of omapatrilat averaged 31%. Total body clearance of omapatrilat (80 L/h) exceeded liver plasma flow. Apparent steady-state volume of distribution of omapatrilat (21 L/kg) was extremely high compared with total body water. Omapatrilat undergoes substantial presystemic first-pass metabolism after oral administration. Omapatrilat is eliminated primarily by metabolism, and its metabolites are eliminated primarily in urine. Extrahepatic organs may be involved in the elimination of omapatrilat. Plasma concentrations of omapatrilat exhibit a prolonged terminal elimination phase, which represents elimination from a deep compartment.
Malhotra
B K
BK
Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000, USA.
Iyer
R A
RA
Soucek
K M
KM
Behr
D
D
Liao
W C
WC
Mitroka
J G
JG
Kaul
S
S
Cohen
M B
MB
Knupp
C A
CA
D000042:Absorption; D000284:Administration, Oral; D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000493:pharmacokinetics*; D019540:Area Under Curve; D001682:Biological Availability; D002250:Carbon Radioisotopes; D018592:Cross-Over Studies; D006801:Humans; D008297:Male; D011725:Pyridines / Q000009:adverse effects / Q000493:pharmacokinetics*; D013841:Thiazepines / Q000009:adverse effects / Q000493:pharmacokinetics*; D014018:Tissue Distribution
D000806:Angiotensin-Converting Enzyme Inhibitors; D002250:Carbon Radioisotopes; D011725:Pyridines; D013841:Thiazepines; C106266:omapatrilat